Kailera Therapeutics, Inc.
KLRADrugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
3
Next Catalyst
Aug 25, 2026
20dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
Ribupatide
Obesity
KAI-9531
Obesity With Diabetes
Semaglutide
Obesity
KAI-7535
Obesity
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ribupatide | Phase 3 | Obesity | - | - |
KAI-9531 | Phase 3 | Obesity With Diabetes | - | - |
Semaglutide | Phase 3 | Obesity | - | - |
KAI-7535 | Phase 2 | Obesity | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Kailera Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Kailera Therapeutics, Inc.'s (KLRA) pipeline across Phase 3, Phase 2. Its lead program is Ribupatide (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kailera Therapeutics, Inc.'s next FDA catalyst?→
Kailera Therapeutics, Inc.'s (KLRA) next tracked catalyst is a Earnings expected August 25, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KLRA biotech catalysts?→
Add KLRA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kailera Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.